Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.

Gilbert H. Kliman net worth and biography

Gilbert Kliman Biography and Net Worth

Director of Glaukos

Dr. Kliman has served as a member of our Board of Directors since 2007, with a brief hiatus from August 2019 through March 2020 relating to the company’s acquisition of Avedro, Inc. (an ophthalmic pharmaceutical and medical technology company for which Dr. Kliman also served on the board of directors). Dr. Kliman has been a partner of InterWest Partners, a venture capital firm, since 1996, and has been a managing director there since 1999. Dr. Kliman served on the board of directors of Epocrates, Inc. (acquired by athenahealth, Inc.) from 1999 to 2011, and IntraLase Corp. (acquired by Advanced Medical Optics, Inc.) from 2000 to 2007. From 1995 to 1996, Dr. Kliman was an investment manager at Norwest Venture Partners, a venture capital firm. From 1989 to 1992, Dr. Kliman served as an associate at TA Associates, a private equity investment firm. Dr. Kliman is a board-certified ophthalmologist and completed a retina research fellowship at Massachusetts Eye and Ear Infirmary and residency training at Wills Eye Hospital. Dr. Kliman holds a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from the Stanford Graduate School of Business. Since June 2020, Dr. Kliman has served on the board of directors for STAAR Surgical Company, and also sits on the board of Doximity, Inc, a board he joined in 2011. He also serves as a director on the executive board of ORBIS International, a global non-profit focused on preventing avoidable blindness.

What is Gilbert H. Kliman's net worth?: The estimated net worth of Gilbert H. Kliman is at least $3.05 million as of March 7th, 2024. Dr. Kliman owns 30,620 shares of Glaukos stock worth more than $3,046,078 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. Kliman may own. Learn More about Gilbert H. Kliman's net worth.
How do I contact Gilbert H. Kliman?: The corporate mailing address for Dr. Kliman and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at [email protected]. Learn More on Gilbert H. Kliman's contact information.
Has Gilbert H. Kliman been buying or selling shares of Glaukos?: Gilbert H. Kliman has not been actively trading shares of Glaukos during the last quarter. Most recently, Gilbert H. Kliman sold 5,000 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $88.25, for a transaction totalling $441,250.00. Following the completion of the sale, the director now directly owns 30,620 shares of the company's stock, valued at $2,702,215. Learn More on Gilbert H. Kliman's trading history.
Who are Glaukos' active insiders?: Glaukos' insider roster includes Thomas Burns (CEO), Joseph Gilliam (CFO), Gilbert Kliman (Director), Marc Stapley (Director), and Alex Thurman (CFO). Learn More on Glaukos' active insiders.
Are insiders buying or selling shares of Glaukos?: During the last year, insiders at the medical instruments supplier sold shares 41 times. They sold a total of 725,957 shares worth more than $60,475,590.77. The most recent insider tranaction occured on April, 8th when CFO Alex R Thurman sold 1,372 shares worth more than $137,940.88. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.
Information on this page was last updated on 4/8/2024.

Gilbert H. Kliman Insider Trading History at Glaukos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Sell	5,000	$88.25	$441,250.00	30,620
2/27/2024	Sell	8,000	$92.00	$736,000.00	8,347
8/4/2023	Sell	10,000	$74.56	$745,600.00	29,725
8/5/2022	Sell	3,362	$53.01	$178,219.62	27,305
2/19/2019	Buy	25,000	$14.00	$350,000.00
8/30/2018	Sell	502,760	$60.39	$30,361,676.40

Gilbert H. Kliman Buying and Selling Activity at Glaukos

Glaukos Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $99.48

$98.53

$100.60

50 Day Range

MA: $92.42

$84.31

$101.19

2 Week Range

Now: $99.48

$45.38

$103.66

Volume

288,895 shs

Average Volume

481,113 shs

Market Capitalization

$4.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Urgent Nvidia Warning

From Altimetry | Ad

Click here to access…